文献速递肿瘤 PET/CT

18F-FDG PET改善弥漫性大B细胞淋巴瘤基线临床预测指标:HOVON-84研究

18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.
PubMed 文献 · J Nucl Med · 2021-10-21

该研究基于HOVON-84随机临床试验,评估基线代谢肿瘤体积(MTV)和中期PET(I-PET)在年龄调整国际预后指数(aaIPI)基础上对弥漫性大B细胞淋巴瘤2年无进展生存(PFS)的预测增值。结果显示I-PET4后ΔSUVmax独立预测2年PFS(HR 5.0),且ΔSUVmax优于Deauville评分(DS);aaIPI联合ΔSUVmax可区分高危与低危组。

要点

  • I-PET4的ΔSUVmax独立预测2年PFS,HR为5.0。
  • ΔSUVmax的预测性能优于Deauville评分(DS)。
  • aaIPI联合ΔSUVmax可提高风险分层准确性。

核心结论

  • 在弥漫性大B细胞淋巴瘤中,4周期R(R)-CHOP14后的I-PET对aaIPI预测2年PFS有增值作用,两者均为独立反应生物标志物。
  • 外部验证表明ΔSUVmax在2年PFS预测上优于DS。

研究设计与样本

  • 基于HOVON-84随机临床试验(EudraCT 2006-005174-42),中央审查I-PET4扫描并使用DS( cutoff 4-5)评估。
  • 测量ΔSUVmax(预设 cutoff 70%)和基线MTV,获取2年PFS的多变量风险比(HR)、阳性预测值(PPV)和阴性预测值(NPV)。
  • 共审查513例I-PET4扫描(DS),ΔSUVmax和基线MTV分别可评估367例和296例患者。

主要发现

  • 所有PET反应标准的I-PET NPV在82%至86%之间。
  • ΔSUVmax的单变量HR和PPV分别为4.8%和53%,优于DS的3.1%和38%。
  • aaIPI和ΔSUVmax独立预测2年PFS(HR分别为3.2和5.0);加入MTV带来轻微改善。
  • 低或低-中危aaIPI联合ΔSUVmax>70%(37%患者)的NPV为93%;高-中或高危aaIPI联合ΔSUVmax≤70%的PPV为65%。

关键数值与推荐

  • DS cutoff为4-5。
  • ΔSUVmax预设cutoff为70%。
  • I-PET4指4周期R(R)-CHOP14后的观察性PET扫描。

临床怎么用

  • 对于弥漫性大B细胞淋巴瘤患者,可在aaIPI基础上结合I-PET4的ΔSUVmax进行风险分层。
  • ΔSUVmax>70%且aaIPI低/低-中危者2年PFS概率较高(NPV 93%)。
  • ΔSUVmax≤70%且aaIPI高-中/高危者2年PFS概率较低(PPV 65%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to determine the added value of baseline metabolic tumor volume (MTV) and interim PET (I-PET) to the age-adjusted international prognostic index (aaIPI) to predict 2-y progression-free survival (PFS) in diffuse large B-cell lymphoma. Secondary objectives were to investigate optimal I-PET response criteria (using Deauville score [DS] or quantitative change in SUVmax [ΔSUVmax] between baseline and I-PET4 [observational I-PET scans after 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone administered in 2-wk intervals with intensified rituximab in the first 4 cycles [R(R)-CHOP14]). Methods: I-PET4 scans in the HOVON-84 (Hemato-Oncologie voor Volwassenen Nederland [Haemato Oncology Foundation for Adults in the Netherlands]) randomized clinical trial (EudraCT 2006-005174-42) were centrally reviewed using DS (cutoff, 4-5). Additionally, ΔSUVmax (prespecified cutoff, 70%) and baseline MTV were measured. Multivariable hazard ratio (HR), positive predictive value (PPV), and negative predictive value (NPV) were obtained for 2-y PFS. Results: In total, 513 I-PET4 scans were reviewed according to DS, and ΔSUVmax and baseline MTV were available for 367 and 296 patients. The NPV of I-PET ranged between 82% and 86% for all PET response criteria. Univariate HR and PPV were better for ΔSUVmax (4.8% and 53%, respectively) than for DS (3.1% and 38%, respectively). aaIPI and ΔSUVmax independently predicted 2-y PFS (HR, 3.2 and 5.0, respectively); adding MTV brought about a slight improvement. Low or low-intermediate aaIPI combined with a ΔSUVmax of more than 70% (37% of patients) yielded an NPV of 93%, and the combination of high-intermediate or high aaIPI and a ΔSUVmax of 70% or less yielded a PPV of 65%. Conclusion: In this study on diffuse large B-cell lymphoma, I-PET after 4 cycles of R(R)-CHOP14 added predictive value to aaIPI for 2-y PFS, and both were independent response biomarkers in a multivariable Cox model. We externally validated that ΔSUVmax outperformed DS in 2-y PFS prediction.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Burggraaff CN, Eertink JJ, Lugtenburg PJ, et al. 18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study. J Nucl Med. 2021. PMID: 34675112. doi:10.2967/jnumed.121.262205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。